Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Accumulated Expenses (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Accumulated Expenses for 4 consecutive years, with $8.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Accumulated Expenses rose 304.16% year-over-year to $8.1 million, compared with a TTM value of $8.1 million through Sep 2023, up 304.16%, and an annual FY2022 reading of $6.2 million, up 156.43% over the prior year.
  • Accumulated Expenses was $8.1 million for Q3 2023 at Terns Pharmaceuticals, roughly flat from $8.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.0 million in Q4 2020 and bottomed at $679000.0 in Q1 2022.
  • Average Accumulated Expenses over 4 years is $4.3 million, with a median of $4.3 million recorded in 2021.
  • Peak annual rise in Accumulated Expenses hit 370.62% in 2022, while the deepest fall reached 83.55% in 2022.
  • Year by year, Accumulated Expenses stood at $9.0 million in 2020, then crashed by 73.32% to $2.4 million in 2021, then surged by 156.43% to $6.2 million in 2022, then soared by 30.72% to $8.1 million in 2023.
  • Business Quant data shows Accumulated Expenses for TERN at $8.1 million in Q3 2023, $8.0 million in Q2 2023, and $832000.0 in Q1 2023.